INTRODUCTION
============

Hepatitis C virus (HCV) infects \>170 million people worldwide and causes chronic liver disease, liver cirrhosis, and hepatocellular carcinoma (HCC).^[@bib1]^ HCV infection is one of the most common infections affecting \~1.5--2 million people in Japan, where \>30,000 deaths from HCC occur each year.^[@bib2]^ According to the World Health Organization survey involving 182 countries in 2008, the number of deaths from liver cancer in Japan ranked second in the world, after only China.^[@bib3],\ [@bib4]^

Moreover, HCV induces extrahepatic manifestations including glomerular disease, hematologic diseases such as cryoglobulinemia and lymphoma, autoimmune disorders such as thyroiditis, and dermatologic conditions such as lichen planus (LP) and porphyria cutanea tarda.^[@bib5],\ [@bib6]^

Until recently, the pegylated interferon (IFN) and ribavirin (RBV) regimen was the standard therapy for HCV chronic hepatitis. However, this combination therapy could achieve sustained virological response (SVR) rates of only 40--50% in patients with genotype 1, and is associated with significant gastrointestinal, hematological, and psychiatric side effects.^[@bib7],\ [@bib8]^ The currently developed IFN-free, direct-acting antivirals (DAAs) used to treat HCV infection have low side effect profiles and high efficacy.^[@bib9],\ [@bib10],\ [@bib11]^

In July 2014, Japan approved the use of a combination therapy with daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 protease inhibitor), making it the first approved, all-oral, IFN-/RBV-free DAAs therapy. One year later, Japan's Ministry of Health, Labour and Welfare approved Harvoni, a combination of sofosbuvir (nucleotide polymerase inhibitor) and ledipasvir (NS5A inhibitor, as the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C (CH-C)).

LP is a chronic, mucocutaneous disease that can affect the oral mucosa, skin, genital mucosa, scalp, and nails. LP is considered as one of the extrahepatic manifestations of HCV infection.^[@bib12],\ [@bib13]^ Oral LP (OLP) can develop, become exacerbated, and persist in patients receiving IFN treatment for hepatitis C.^[@bib14],\ [@bib15],\ [@bib16],\ [@bib17]^ In previous studies, we examined hepatitis C patients for oral lesions before, during, and after IFN treatment; OLP was seen in 11.7--16.7%.^[@bib14],\ [@bib17]^ Furthermore, in another study, we reported the case of a 65-year-old, Japanese, CH-C patient presenting with exacerbation of preexisting erosive OLP, and the appearance of cutaneous LP, and larynx leukoplakia following IFN and RBV therapy.^[@bib15]^ The larynx leukoplakia had developed into malignancy, subsequently.

Safety and efficacy of IFN-free DAAs in patients with OLP have not been proved yet. In this study, we examined the disease course in patients with HCV-associated OLP, who received treatment with IFN-free DAAs using the DCV/ASV combination therapy.

METHODS
=======

Patients
--------

Seven patients with clinically and/or histopathologically confirmed HCV-related OLP who received IFN-free treatment with DCV/ASV at the Kurume University Hospital in Japan from October, 2014 to February, 2015 were enrolled in the study ([Table 1](#tbl1){ref-type="table"}). The subjects included four males and three females (average age; 73.9), of whom five suffered from CH-C, one from CH-C with post-HCC treatment, and one from HCV-related liver cirrhosis (LC-C), Child-Pugh Class A with post-HCC treatment. One of the subjects (patient number 6) presented with cutaneous LP. Five of the seven patients were treated with the IFN and RBV regimen therapy at the Kurume University Hospital in the past. Hepatologists and an oral surgeon examined all patients. All patients with HCV genotype 1 received both DCV 60 mg once daily and ASV 100 mg twice daily for 24 weeks.

Outcome for OLP before and after treatment with DAAs
----------------------------------------------------

The OLP lesions were clinically examined in all patients before, during, and at 24 weeks after the end of the DCV/ASV combination therapy.

Serological assays
------------------

All subjects were tested for red blood cell count, white blood cell count, platelet count, hemoglobin, and the following liver function tests: serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, alpha-fetoprotein, total bilirubin, direct bilirubin, total cholesterol, total protein, and albumin.

Evaluation of liver diseases
----------------------------

Anti-HCV was measured using a chemiluminescent enzyme immunoassay kit (Lumipulse II HCV, Fujirebio; Tokyo, Japan). HCV RNA levels were analyzed in serum by quantitative polymerase chain reaction assay (COBAS AMPLICOR HCV MONITOR v 2.0 Test, COBAS AmpliPrep/COBAS Taq-Man HCV Test, Roche Molecular Systems; Branchburg, NJ, USA).^[@bib18],\ [@bib19]^ HCV genotype was determined by polymerase chain reaction assay using a mixture of primers for the subtype, as reported previously.^[@bib20]^ Ultrasonographic examination was performed on all patients to investigate the shape of the liver and to identify lesions within the liver. Computed tomography was also performed on some patients. We used other possible predictors of progression of LC, including serum albumin, total bilirubin, prothrombin time, and platelet. Liver biopsy was performed in some patients.

Ethical considerations
----------------------

This investigation was undertaken with the understanding and consent of each participating subject, and was conducted in full accordance with the ethical principles of the World Medical Association Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Saga Medical School (reference number: 27--36) in accordance with the Declaration of Helsinki. Written informed consent for participation in the study was obtained from each patient.

Statistical analysis
--------------------

All data were expressed as mean±s.e. Differences between baseline and SVR24 were analyzed using Wilcoxon signed-rank test. Differences were significant at *P\<*0.05 (two-tailed). All statistical analyses were conducted using JMP Version 11.1.1 software (SAS Institute, Cary, NC, USA). The level of statistical significance was defined as *P\<*0.05.

RESULTS
=======

Treatment outcomes for liver disease
------------------------------------

All subjects presented with undetectable HCV RNA levels at 8 weeks after DAAs treatment. Furthermore, all subjects achieved SVR 12 weeks (SVR12) and 24 weeks (SVR24) after the end of treatment. A comparison of the biochemical data at baseline and SVR24 is shown in [Table 2](#tbl2){ref-type="table"}. Serum aspartate aminotransferase and alanine aminotransferase levels, and alpha-fetoprotein were decreased, whereas albumin levels were increased. No systemic clinical adverse events were observed in the patients.

Outcomes for OLP
----------------

No deterioration of symptoms was observed in the patients during DAAs treatment. The symptoms of OLP/cutaneous LP had subsided in all patients; the lesions had disappeared in four, and improved in three of the seven patients after SVR24 ([Table 1](#tbl1){ref-type="table"}; [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Disappearance of OLP lesions on the buccal mucosa, bilaterally, and decrease in erosive lesions on the tongue and lower lip were observed in a 59-year-old Japanese male patient ([Table 1](#tbl1){ref-type="table"}). Similar findings were observed in another 77-year-old male patient. In one of the patients, a 72-year-old Japanese female, the OLP lesions appeared to fade away until a slight white spot remained. We conducted an extended follow-up for OLP. Although OLP lesions did not completely disappear about three patients, the symptom and the discomfort of two patients (number 4 after SVR40 and number 7 after SVR52 in [Table 1](#tbl1){ref-type="table"}) disappeared, and the lesion of one patient (number 2 in [Table 1](#tbl1){ref-type="table"}) reduced after SVR52.

Three patients received topical steroid therapy for the erosion of OLP before DAAs treatment, and only one received steroid therapy after treatment.

DISCUSSION
==========

The elimination of HCV reduces not only the development of HCC, but also the onset of conditions such as malignant lymphoma, Type 2 diabetes, and chronic kidney disease.^[@bib21],\ [@bib22],\ [@bib23]^ Furthermore, the elimination of a virus has been shown to reduce bone fracture, osteoporosis, and the development of hemorrhagic stroke.^[@bib24],\ [@bib25]^ In a previous study, we have reported that the disappearance of HCV RNA and improvements in liver function over a period of \>3 years appears to resolve OLP lesions.^[@bib26]^ Thus, the elimination of HCV inhibits the onset of various extrahepatic manifestations.

In 2014, a 24-week treatment with DCV/ASV provided a highly effective option for patients who had no effective treatment options available (ineligible for, or intolerant to IFN-based therapy) and for those who did not achieve SVR following prior treatment.^[@bib9]^ SVR24 was achieved by 87.4% of the IFN-ineligible/-intolerant patients and 80.5% of the nonresponders (null and partial patients); rates were similar in cirrhosis (90.9%) and noncirrhosis (84.0%) patients, and in patients with *IL28B* (rs12979869) CC (84.5%) or non-CC (84.8%) genotypes.

In the present study, all subjects (*IL28B* (rs8099917) non-TT; six patients, TT; one patient) achieved SVR12 and SVR24. This result was comparable with the phase 3 study of DCV/ASV therapy in Japan.^[@bib9]^

Recently, Garcovich *et al.*^[@bib27]^ reported that it is possible, but not proven that more effective and rapid antiviral responses observed with IFN-free antiviral regimens will improve outcomes in clinical settings, especially when HCV infection is burdened by extrahepatic manifestations. Makara *et al.*^[@bib28]^ reported a successful case of HCV-associated mixed cryoglobulinemia effectively treated with an IFN-free combination of newly approved DAAs and RBV. However, there are no reports about IFN-free DAA treatment for HCV-associated OLP. The safety and efficacy of IFN-free DAA therapy in patients with OLP has not been proven yet. In the present study, we have reported the outcomes of HCV-associated OLP in patients who received successful treatment with IFN-free DAAs, using the DCV/ASV combination therapy. We consider that OLP lesions may completely disappear by long follow-up in patients after the extermination of HCV.

In this study, the lesions of OLP in three of the seven patients did not completely disappear after IFN-free DAAs therapy. Presence of smoking and diabetes were considered as one of the reason why OLP lesions did not disappear.

Tobacco use was reported to be a risk factor that develops cancer in OLP.^[@bib29]^ Klosek *et al.*^[@bib30]^ reported smoking in OLP patients correlated with both microvessel density and c-Met-positive staining. The authors showed the c-Met expression with smoking habit was statistically significant within the OLP group (*P\<*10^−6^). c-MET is the receptor for hepatocyte growth factor, tyrosine kinase with downstream targets involved in a variety of cellular signaling pathways including proliferation, motility, migration, and invasion.^[@bib31]^ c-Met receptor is expressed selectively in several normal human epithelial tissues as well as in carcinoma.

Diabetes has been also supposed to have a role in the OLP pathogenesis.^[@bib32]^ Baykal *et al.*^[@bib33]^ revealed the prevalence of metabolic syndrome in LP patients. Among the metabolic syndrome criteria, mean fasting blood glucose and diastolic blood pressure were also significantly higher in LP patients than in controls (*P*=0.012 and *P*=0.021, respectively). We previously reported an association OLP and insulin resistance induced by HCV infection.^[@bib34],\ [@bib35]^

Conventionally, there were problems such as inability to complete IFN therapy due to worsening of OLP lesions following IFN therapy. IFN therapy has led to the development of oral mucosal lesions, resulting in oral candidiasis and inhibited salivary secretion.^[@bib36]^ Treatment of HCV infection using IFN-free therapeutic methods may help improve the associated extrahepatic manifestations seen in the patients. Awareness of extrahepatic manifestations is necessary not only for the hepatologist, but also for the non-hepatologist. Guidelines on DAA therapy for the treatment of HCV-associated extrahepatic manifestations in Japan are expected to come into effect immediately.

Our study showed that patients with HCV-associated OLP were treated safely and effectively with IFN-free DAA therapy. We intend to conduct further studies involving larger samples in future.

Study Highlights
================
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![Clinical photographs showing disappearance of OLP lesions from the buccal mucosa of the patient. (**a**) OLP lesions affecting the buccal mucosa on both sides of the mouth. (**b**) Disappearance of OLP 13 months later, following the treatment with DAAs. DAAs, direct-acting antivirals; OLP, oral lichen planus.](ctg201637f1){#fig1}

![Clinical photograph showing the disappearance of OLP lesions from the buccal mucosa of another patient. (**a**) OLP lesions affecting the buccal mucosa on both sides of the mouth. (**b**) Disappearance of OLP 13 months later, following the treatment with DAAs. DAAs, direct-acting antivirals; OLP, oral lichen planus.](ctg201637f2){#fig2}

###### The characteristics of seven patients with OLP

  -------------------------------------------- ------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------- --------------------------------------------------------- ----------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  No.                                          1                         2                                                                                                3                                                   4                                                         5                             6                                                   7
  Sex                                          F                         M                                                                                                M                                                   F                                                         M                             F                                                   M
  Age                                          72                        59                                                                                               76                                                  72                                                        84                            77                                                  77
  Liver disease                                CH-C                      CH-C                                                                                             CH-C                                                CH-C                                                      CH-C, post HCC                LC-C, post HCC                                      CH-C
  HCV genotype/ level of HCV RNA               Ib/high                   Ib/high                                                                                          Ib/high                                             Ib/high                                                   Ib/high                       Ib/high                                             Ib/high
  *IL28B* gene (rs8099917) TT/non-TT           Non-TT                    Non-TT                                                                                           Non-TT                                              Non-TT                                                    TT                            Non-TT                                              Non-TT
  History of treatment of IFN                  Yes                       Yes                                                                                              No                                                  Yes                                                       No                            Yes                                                 Yes
  Exacerbation of OLP at past IFN therapy      Yes                       Yes                                                                                              ---                                                 Yes                                                       ---                           Yes                                                 Yes
  Systemic disease except the liver disease    No                        Hypertension, diabetes mellitus, and ventricular extrasystole                                    Asthma, reflux esophagitis, and gallbladder polyp   Postoperative coxarthrosis                                Hypertension and arrhythmia   Hypothyroidism and osteoporosis                     Hypertension and post larynx cancer
  Presence or absence of smoking               Never smoker              Ever smoker                                                                                      Smoking cessation                                   Never smoker                                              Never smoker                  Never smoker                                        Smoking cessation
  Effect of DAAs therapy                       SVR24                     SVR24                                                                                            SVR24                                               SVR24                                                     SVR24                         SVR24                                               SVR24
  Type of OLP before DAA therapy               Erosive                   Erosive                                                                                          Reticular                                           Reticular                                                 Reticular                     Erosive                                             Erosive and reticular
  Sites of OLP before DAA therapy              Bilateral buccal mucosa   Bilateral buccal mucosa, tongue, and lower lip                                                   Bilateral buccal mucosa                             Bilateral buccal mucosa                                   Bilateral buccal mucosa       Bilateral buccal mucosa and bilateral calves skin   Bilateral buccal mucosa and lower lip
  Topical steroids to OLP before DAA therapy   Not received              Received                                                                                         Not received                                        Not received                                              Not received                  Received                                            Received
  Findings of OLP after SVR24                  All disappearance         Lesions at buccal mucosa: disappearance. Lesions at tongue and lower lip: reduction of erosion   All disappearance                                   Lesion became unclear, but a slight white spot remained   All disappearance             All disappearance                                   Lesions at buccal mucosa: disappearance. Lesions at lower lip: disappearance of erosion, but a slight white spot remained
  Turning point of OLP after SVR24             Disappearance             Improvement                                                                                      Disappearance                                       Improvement                                               Disappearance                 Disappearance                                       Improvement
  Topical steroids to OLP after DAA therapy    Not received              Received                                                                                         Not received                                        Not received                                              Not received                  Not received                                        Not received
  -------------------------------------------- ------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------- --------------------------------------------------------- ----------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------

CH-C, chronic hepatitis C; DAAs, direct-acting antivirals; F, female; IFN, interferon; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LC-C, liver cirrhosis type C; M, male; non-TT, minor allele; OLP, oral lichen planus; SVR, sustained virological response; TT, major allele.

###### Comparison of the biochemical data in baseline and SVR24

                                 **Baseline**   **SVR24**      ***P* value**
  ------------------ ----------- -------------- ------------- ---------------
  BMI                Mean±s.d.   19.1±8.3       23.1±4.1          0.0469
  AST (U/I)          Mean±s.d.   57.1±29.1      28.9±9.4          0.0313
  ALT (U/I)          Mean±s.d.   52.9±31.1      18.4±4.7            NS
  ALP (U/l)          Mean±s.d.   357.1±140.9    303.9±110.0         NS
  γGTP (U/l)         Mean±s.d.   36.6±20.7      25.4±13.1           NS
  T.pro (g/dl)       Mean±s.d.   7.40±0.4       7.67±0.4            NS
  Alb (g/dl)         Mean±s.d.   3.83±0.6       4.19±0.3            NS
  BUN (mg/dl)        Mean±s.d.   15.1±2.5       17.0±3.1          0.0469
  AFP (ng/dl)        Mean±s.d.   40.5±65.0      5.9±4.2             NS
  PIVKAII (mAU/ml)   Mean±s.d.   18.8±5.8       25.2±6.0          0.0313
  RBC (× 10^4^/μl)   Mean±s.d.   431±36.9       438.6±25.4          NS
  Hb (g/dl)          Mean±s.d.   14.0±1.5       13.9±1.1            NS
  WBC (μl)           Mean±s.d.   46.0±12.7      52.0±20.8           NS
  Plt (× 10^4^/μl)   Mean±s.d.   13.6±4.2       13.8±4.6            NS

AFP, alpha-fetoprotein; Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; γGTP, γ-glutamyl transpeptidase; Hb, hemoglobin; NS, not significant; PIVKAII, protein induced by vitamin K absence or antagonists II; Plt, platelet; RBC, red blood cell; T.pro, total protein; WBC, white blood cell.
